Barretts esaphagus clinical trial

Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation. Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission.

Mayo Clinic does not endorse any of the third party products and services advertised. A single copy of these materials may be reprinted for noncommercial personal use only. See more conditions. Clinical Trials. The sample size is patients with high or low grade Barrett's dysplasia. Celecoxib is administered orally, mg twice per day; the dosing schedule for placebo is the same.

Randomization is stratified by dysplasia grade and by clinic. Stratified cells have a protective function, preventing harmful substances from coming in contact with underlying cells; columnar cells absorb nutrients from food. In the Gastroenterology paper, Shivdasani and his colleagues investigated these seemingly intestinal cells at the molecular level. Each type of cell — be it a brain, bone, or nerve cell — has a distinctive chromatin signature.

The finding also left considerable ambiguity: did the tissue consist of a mix of stomach and intestinal cells, or of cells with a partly stomach and partly intestinal nature? The answer came when advances in technology enabled researchers to probe chromatin organization within single cells.

But it left open the question of how stomach cells take on some intestinal cell qualities. The Genes and Development paper takes an important step in solving that conundrum. That step involves a transcription factor — a protein that controls gene activity — called HNF4A, which is normally present in stomach cells at low levels.

Detailed Description:. FDA Resources. Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Patients with a visable lesion that is less than 1cm. Outcome Measures. Eligibility Criteria.

Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Inclusion Criteria: Male or female, age 18 to Patient must have Barrett's Esophagus. It is not necessary that each patient have endoscopy for the sole purpose of enrollment. Must agree to allow their clinical information to be collected, stored, analyzed and reported. Must agree to fill out patient questionnaires in conjunction with the research study assistant assigned to this protocol either in person or via telephone contact at designated timepoints.

Exclusion Criteria: Intestinal metaplasia of the cardia, without an esophageal columnar lining. Unable to provide informed consent. Unable or unwilling to undergo endoscopic procedures.

Contacts and Locations.